Chronic Noninfectious Uveitis: From Pathophysiology to Management

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 4138

Special Issue Editor


E-Mail Website
Guest Editor
Center of Ocular Inflammation, Charité, Berlin, Germany
Interests: ocular immune-mediated disorders; keratitis; immune pharmacology; uveitis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic noninfectious uveitis remains a leading cause of visual impairment and represents a significant burden of legal and economic blindness. Although the molecular/immunological mechanisms of noninfectious uveitis have been analysed, leading to new findings, many details of the chronic inflammatory processes remain unknown. Complex interactions, e.g., with regard to genotype and the microbiome, are increasingly discovered in chronic intraocular inflammation. The relevance of immunosenescence and inflammaging is widely unknown, but they are thought to modulate disease evolution. This complex immune-biologic scenario is often highly destructive and remains a challenge for early and accurate diagnosis and effective management. Therefore, the development of improved diagnostic and therapeutic modalities, in particular OCT and immune modulatory agents, has received intense attention from the uveitis research community.

This Special Issue aims to provide expert insight into the current diagnostic and therapeutic procedures for chronic uveitis. In addition, current developments regarding biomarkers for monitoring chronic inflammation will be included. Both original papers and review articles will be considered.

Dr. Uwe Pleyer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • artificial intelligence
  • biomarker
  • immune pharmacology
  • immune regulation
  • immune system
  • chronic inflammation
  • uveitis
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 1024 KiB  
Communication
Presence of Choroidal Caverns in Patients with Posterior and Panuveitis
by Tedi Begaj, Amy Yuan, Ines Lains, Ashley Li, Samuel Han, Gayatri Susarla, Ravi Parikh and Lucia Sobrin
Biomedicines 2023, 11(5), 1268; https://doi.org/10.3390/biomedicines11051268 - 25 Apr 2023
Cited by 1 | Viewed by 1384
Abstract
Choroidal caverns (CCs) have been described in association with age-related macular degeneration and pachychoroid disease. However, it is unknown if caverns are found in patients with chronic non-infectious uveitis (NIU). Herein, we evaluated patients with NIU who had optical coherence tomography and indocyanine [...] Read more.
Choroidal caverns (CCs) have been described in association with age-related macular degeneration and pachychoroid disease. However, it is unknown if caverns are found in patients with chronic non-infectious uveitis (NIU). Herein, we evaluated patients with NIU who had optical coherence tomography and indocyanine green angiography for CCs. Clinical and demographic characteristics were extracted from the chart review. Univariate and multivariate mixed-effects logistical models were used to assess the association between clinical and demographic factors and the presence of CCs. One hundred thirty-five patients (251 eyes) met the inclusion criteria: 1 eye had anterior uveitis, 5 had intermediate uveitis, 194 had posterior uveitis, and 51 had panuveitis. The prevalence of CCs was 10%. CCs were only observed in patients with posterior and panuveitis, with a prevalence of 10.8% and 7.8%, respectively. Multifocal choroiditis (MFC) was the type of uveitis where CCs were most frequently observed, with 40% of eyes with MFC having CCs. In addition, male sex (p = 0.024) was associated with CCs. There was no significant difference in the degree of intraocular inflammation or mean subfoveal choroidal thickness between CC+ and CC− eyes. This is the first study to describe CCs in uveitis. Overall, these findings suggest that caverns may be a sequela of structural and/or vascular perturbations in the choroid from uveitis. Full article
(This article belongs to the Special Issue Chronic Noninfectious Uveitis: From Pathophysiology to Management)
Show Figures

Figure 1

13 pages, 914 KiB  
Article
Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset
by Michael Ostrovsky, Amir Rosenblatt, Salam Iriqat, Abdallah Shteiwi, Yael Sharon, Michal Kramer, Vicktoria Vishnevskia-Dai, Shaul Sar, Yosif Boulos, Oren Tomkins-Netzer, Natalie Lavee, Yael Ben-Arie-Weintrob, Hadas Pizem, Tamar Hareuveni-Blum, Marina Schneck, Raz Gepstein, Dua Masarwa, Nakhoul Nakhoul, Erez Bakshi, Shiri Shulman, Michaella Goldstein, Dan Ramon, Marina Anouk and Zohar Habot-Wilneradd Show full author list remove Hide full author list
Biomedicines 2023, 11(2), 624; https://doi.org/10.3390/biomedicines11020624 - 19 Feb 2023
Cited by 5 | Viewed by 2319
Abstract
Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments [...] Read more.
Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and outcomes between three age groups: juvenile (<18 years), adult (18–39 years) and late (≥40 years) disease onset. The study included 175 ocular BD patients (303 eyes) from Israel and Palestine: juvenile-onset (n = 25, 14.3%), adult-onset (n = 120, 68.6%) and late-onset (n = 30, 17.1%). Most patients in all groups were male. Systemic manifestations were similar in all groups. Systemic co-morbidities were more common in late-onset patients. Bilateral panuveitis was the most common ocular manifestation in all patients. Non-occlusive retinal vasculitis, peripheral vessel occlusions, cataract and elevated intraocular pressure were found more commonly among juvenile-onset eyes. Anterior uveitis and macular ischemia were most common among late-onset eyes, while branch retinal vein occlusion was most common in adult and late-onset eyes. All patients were treated with corticosteroids. Methotrexate, immunomodulatory combinations and biologic treatments were more commonly used for juvenile-onset patients. All groups had a similar visual outcome. Our study showed that patients with ocular BD have varied ocular manifestations and require different treatments according to age of disease onset, but visual outcome is similar. Full article
(This article belongs to the Special Issue Chronic Noninfectious Uveitis: From Pathophysiology to Management)
Show Figures

Figure 1

Back to TopTop